{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:13:37Z","timestamp":1792199617194,"version":"4.4.0"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat and economic burden. The pandemic is still ongoing and the SARS-CoV-2 variants are still emerging constantly, resulting in an urgent demand for new drugs to treat this disease. Molnupiravir, a biological prodrug of NHC (\u03b2-D-N(4)-hydroxycytidine), is a novel nucleoside analogue with a broad-spectrum antiviral activity against SARS-CoV, SARS-CoV-2, Middle East respiratory syndrome coronavirus (MERS-CoV), influenza virus, respiratory syncytial virus (RSV), bovine viral diarrhea virus (BVDV), hepatitis C virus (HCV) and Ebola virus (EBOV). Molnupiravir showed potent therapeutic and prophylactic activity against multiple coronaviruses including SARS-CoV-2, SARS-CoV, and MERS-CoV in animal models. In clinical trials, molnupiravir showed beneficial effects for mild to moderate COVID-19 patients with a favorable safety profile. The oral bioavailability and potent antiviral activity of molnupiravir highlight its potential utility as a therapeutic candidate against COVID-19. This review presents the research progress of molnupiravir starting with its discovery and synthesis, broad-spectrum antiviral effects, and antiviral mechanism. In addition, the preclinical studies, antiviral resistance, clinical trials, safety, and drug tolerability of molnupiravir are also summarized and discussed, aiming to expand our knowledge on molnupiravir and better deal with the COVID-19 epidemic.<\/jats:p>","DOI":"10.3389\/fimmu.2022.855496","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T01:41:16Z","timestamp":1649036476000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":143,"title":["Molnupiravir and Its Antiviral Activity Against COVID-19"],"prefix":"10.3389","volume":"13","author":[{"given":"Lili","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maochen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxing","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhou","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huahao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25966","article-title":"Clinical Features of Patients With Coronavirus Disease 2019 From a Designated Hospital in Beijing, China","volume":"92","author":"Sun","year":"2020","journal-title":"J Med Virol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.680127","article-title":"Artemether, Artesunate, Arteannuin B, Echinatin, Licochalcone B and Andrographolide Effectively Inhibit SARS-CoV-2 and Related Viruses In Vitro","volume":"11","author":"Hu","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021801","article-title":"A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19","volume":"384","author":"Mitj\u00e0","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06395-1","article-title":"Camostat Mesylate Therapy in Critically Ill Patients With COVID-19 Pneumonia","volume":"47","author":"Sakr","year":"2021","journal-title":"Intensive Care Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30418-5","article-title":"Human Recombinant Soluble ACE2 in Severe COVID-19","volume":"8","author":"Zoufaly","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients With Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe4747","article-title":"Versatile and Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2","volume":"370","author":"Xiang","year":"2020","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031304","article-title":"A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol Monotherapy is Superior to Lopinavir\/Ritonavir in Treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J Infect"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2003725","DOI":"10.1183\/13993003.03725-2020","article-title":"Early Use of Nitazoxanide in Mild COVID-19 Disease: Randomised, Placebo-Controlled Trial","volume":"58","author":"Rocco","year":"2021","journal-title":"Eur Respir J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1888660","article-title":"The In Vitro Antiviral Activity of Lactoferrin Against Common Human Coronaviruses and SARS-CoV-2 is Mediated by Targeting the Heparan Sulfate Co-Receptor","volume":"10","author":"Hu","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/S2666-5247(21)00278-0","article-title":"The Emergence of Powerful Oral Anti-COVID-19 Drugs in the Post-Vaccine Era","volume":"3","author":"Fan","year":"2022","journal-title":"Lancet Microbe"},{"key":"B15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41392-020-00408-z","article-title":"The Effect of Whey Protein on Viral Infection and Replication of SARS-CoV-2 and Pangolin Coronavirus In Vitro","volume":"5","author":"Fan","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in Adults With Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple Combination of Interferon Beta-1b, Lopinavir-Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital With COVID-19: An Open-Label, Randomised, Phase 2 Trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107522","article-title":"Safety and Efficacy of Favipiravir in Moderate to Severe SARS-CoV-2 Pneumonia","volume":"95","author":"Solaymani-Dodaran","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab361","article-title":"Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model","volume":"224","author":"Abdelnabi","year":"2021","journal-title":"J Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized With Severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coviro.2021.04.006","article-title":"Considerations for the Discovery and Development of 3-Chymotrypsin-Like Cysteine Protease Inhibitors Targeting SARS-CoV-2 Infection","volume":"49","author":"Vandyck","year":"2021","journal-title":"Curr Opin Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical Characterization of an Intravenous Coronavirus 3CL Protease Inhibitor for the Potential Treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and Calpain Inhibitors II, XII Inhibit SARS-CoV-2 Viral Replication by Targeting the Viral Main Protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1038\/s41467-021-26760-4","article-title":"Oral Prodrug of Remdesivir Parent GS-441524 is Efficacious Against SARS-CoV-2 in Ferrets","volume":"12","author":"Cox","year":"2021","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4058","article-title":"Plitidepsin has Potent Preclinical Efficacy Against SARS-CoV-2 by Targeting the Host Protein Eef1a","volume":"371","author":"White","year":"2021","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial","volume":"325","author":"L\u00f3pez-Medina","year":"2021","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients With Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in Patients Hospitalized With Covid-19 Pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in Patients Admitted to Hospital With Severe or Critical COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41467-021-21085-8","article-title":"Efficacy and Tolerability of Bevacizumab in Patients With Severe Covid-19","volume":"12","author":"Pang","year":"2021","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202004_20875","article-title":"Eculizumab Treatment in Patients With COVID-19: Preliminary Results From Real Life ASL Napoli 2 Nord Experience","volume":"24","author":"Diurno","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01061-20","article-title":"A Randomized Clinical Trial of the Efficacy and Safety of Interferon \u03b2-1a in Treatment of Severe COVID-19","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-\u03b12b Treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211048139","article-title":"COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab\/Etesevimab, and Casirivimab\/Imdevimab) and Pharmacological Considerations","author":"Nhean","year":"2021","journal-title":"J Pharm Pract"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00162-20","article-title":"Remdesivir Against COVID-19 and Other Viral Diseases","volume":"34","author":"Malin","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22813","article-title":"Therapy for Early COVID-19: A Critical Need","volume":"324","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine Breakthrough Infections With SARS-CoV-2 Variants","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41392-021-00767-1","article-title":"SARS-CoV-2 Variants of Concern Delta: A Great Challenge to Prevention and Control of COVID-19","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41392-021-00592-6","article-title":"SARS-CoV-2 Variants: A New Challenge to Convalescent Serum and mRNA Vaccine Neutralization Efficiency","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00420-w","article-title":"SARS-CoV-2 Vaccination in IBD: More Pros Than Cons","volume":"18","author":"D\u2019Amico","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744242","article-title":"Understanding the Secret of SARS-CoV-2 Variants of Concern\/Interest and Immune Escape","volume":"12","author":"Lou","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients","volume":"386","author":"Jayk Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3390\/antibiotics10111294","article-title":"Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent","volume":"10","author":"Lee","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","article-title":"Developing a Direct Acting, Orally Available Antiviral Agent in a Pandemic: The Evolution of Molnupiravir as a Potential Treatment for COVID-19","volume":"50","author":"Painter","year":"2021","journal-title":"Curr Opin Virol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.trsl.2019.12.002","article-title":"Quantitative Efficacy Paradigms of the Influenza Clinical Drug Candidate EIDD-2801 in the Ferret Model","volume":"218","author":"Toots","year":"2020","journal-title":"Transl Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-18","article-title":"Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An Orally Bioavailable Broad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial Cell Cultures and Multiple Coronaviruses in Mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02428-20","article-title":"Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent With Activity Against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.17.21258639","article-title":"Molnupiravir, an Oral Antiviral Treatment for COVID-19","volume":"14","author":"Fischer","year":"2021","journal-title":"medRxiv"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.3390\/molecules26195795","article-title":"Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19","volume":"26","author":"Imran","year":"2021","journal-title":"Molecules"},{"key":"B54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.coviro.2019.04.002","article-title":"Nucleoside Analogues for the Treatment of Coronavirus Infections","volume":"35","author":"Pruijssers","year":"2019","journal-title":"Curr Opin Virol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01348-19","article-title":"Small-Molecule Antiviral \u03b2-D-N (4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus With a High Genetic Barrier to Resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of Molnupiravir-Induced SARS-CoV-2 Mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00959","article-title":"Neurological Sequelae Resulting From Encephalitic Alphavirus Infection","volume":"7","author":"Ronca","year":"2016","journal-title":"Front Microbiol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1086\/513978","article-title":"Epidemic Venezuelan Equine Encephalitis in La Guajira, Colombia, 1995","volume":"175","author":"Rivas","year":"1997","journal-title":"J Infect Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212628","article-title":"Eastern Equine Encephalitis in Latin America","volume":"369","author":"Carrera","year":"2013","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02395-16","article-title":"Characterization of \u03b2-D-N(4)-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus","volume":"61","author":"Ehteshami","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01965-17","article-title":"\u03b2-D-N (4)-Hydroxycytidine Is a Potent Anti-Alphavirus Compound That Induces a High Level of Mutations in the Viral Genome","volume":"92","author":"Urakova","year":"2018","journal-title":"J Virol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.06.006","article-title":"Biochemistry of Uridine in Plasma","volume":"412","author":"Yamamoto","year":"2011","journal-title":"Clin Chim Acta"},{"key":"B63","article-title":"N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto","author":"Painter","year":"2021","journal-title":"U.S. Patent No 11147826B2"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/ejoc.202001340","article-title":"A High-Yielding Synthesis of EIDD-2801 From Uridine","volume":"2020","author":"Steiner","year":"2020","journal-title":"Eur J Org Chem"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1039\/d0cc05944g","article-title":"A Concise Route to MK-4482 (EIDD-2801) From Cytidine","volume":"56","author":"Vasudevan","year":"2020","journal-title":"Chem Commun (Camb)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.1c00772","article-title":"Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) From Cytidine","volume":"6","author":"Ahlqvist","year":"2021","journal-title":"ACS Omega"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.244-254.2003","article-title":"Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture","volume":"47","author":"Stuyver","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/v7122934","article-title":"Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication","volume":"7","author":"Reynard","year":"2015","journal-title":"Viruses"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104597","article-title":"The Prophylactic and Therapeutic Activity of a Broadly Active Ribonucleoside Analog in a Murine Model of Intranasal Venezuelan Equine Encephalitis Virus Infection","volume":"171","author":"Painter","year":"2019","journal-title":"Antiviral Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/095632020401500102","article-title":"Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARSCoV) by Calpain Inhibitors and Beta-D-N4-Hydroxycytidine","volume":"15","author":"Barnard","year":"2004","journal-title":"Antivir Chem Chemother"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01598-05","article-title":"Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle","volume":"50","author":"Pyrc","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir Promotes SARS-CoV-2 Mutagenesis via the RNA Template","volume":"297","author":"Gordon","year":"2021","journal-title":"J Biol Chem"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100867","article-title":"Decoding Molnupiravir-Induced Mutagenesis in SARS-CoV-2","volume":"297","author":"Men\u00e9ndez-Arias","year":"2021","journal-title":"J Biol Chem"},{"key":"B74","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 Polymerase Stalling by Remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103595","article-title":"The Combined Treatment of Molnupiravir and Favipiravir Results in a Potentiation of Antiviral Efficacy in a SARS-CoV-2 Hamster Infection Model","volume":"72","author":"Abdelnabi","year":"2021","journal-title":"EBioMedicine"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105122","article-title":"A Robust SARS-CoV-2 Replication Model in Primary Human Epithelial Cells at the Air Liquid Interface to Assess Antiviral Agents","volume":"192","author":"Do","year":"2021","journal-title":"Antiviral Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105078","article-title":"A Cell-Based Assay to Discover Inhibitors of SARS-CoV-2 RNA Dependent RNA Polymerase","volume":"190","author":"Zhao","year":"2021","journal-title":"Antiviral Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically Administered Ribonucleoside Analogue MK-4482\/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of Orally Efficacious Influenza Drug With High Resistance Barrier in Ferrets and Human Airway Epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci Transl Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-86289\/v1","article-title":"Orally Delivered MK-4482 Inhibits SARS-CoV-2 Replication in the Syrian Hamster Model","author":"Rosenke","year":"2020","journal-title":"Res Sq"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111642","article-title":"Disease-Drug and Drug-Drug Interaction in COVID-19: Risk and Assessment","volume":"139","author":"Kumar","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105073","article-title":"Remodeling of Immunological Biomarkers in Patients With Chronic Hepatitis C Treated With Direct-Acting Antiviral Therapy","volume":"190","author":"Ribeiro","year":"2021","journal-title":"Antiviral Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2021.122921","article-title":"Development and Validation of Assays for the Quantification of \u03b2-D-N(4)-Hydroxycytidine in Human Plasma and \u03b2-D-N(4)-Hydroxycytidine-Triphosphate in Peripheral Blood Mononuclear Cell Lysates","volume":"1182","author":"Parsons","year":"2021","journal-title":"J Chromatogr B Analyt Technol BioMed Life Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/82_2015_459","article-title":"Antiviral Strategies Based on Lethal Mutagenesis and Error Threshold","volume":"392","author":"Perales","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jama.2019.20225","article-title":"New Flu Antiviral Candidate May Thwart Drug Resistance","volume":"323","author":"Hampton","year":"2020","journal-title":"JAMA"},{"key":"B86","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2020.01.005","article-title":"Next-Generation Direct-Acting Influenza Therapeutics","volume":"220","author":"Toots","year":"2020","journal-title":"Transl Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2106-250","article-title":"An Update of Anti-Viral Treatment of COVID-19","volume":"51","author":"\u015eim\u015fek-Yavuz","year":"2021","journal-title":"Turk J Med Sci"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: A Systematic Review of Literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A Phase 2a Clinical Trial of Molnupiravir in Patients With COVID-19 Shows Accelerated SARS-CoV-2 RNA Clearance and Elimination of Infectious Virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci Transl Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab318","article-title":"Optimal Dose and Safety of Molnupiravir in Patients With Early SARS-CoV-2: A Phase I, Open-Label, Dose-Escalating, Randomized Controlled Study","volume":"76","author":"Khoo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-D-N4-Hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J Infect Dis"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/gey005","article-title":"A Critical Appraisal of the Sensitivity of In Vivo Genotoxicity Assays in Detecting Human Carcinogens","volume":"33","author":"Zeller","year":"2018","journal-title":"Mutagenesis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3201\/eid2212.160123","article-title":"Assessing the Epidemic Potential of RNA and DNA Viruses","volume":"22","author":"Woolhouse","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"180017","DOI":"10.1038\/sdata.2018.17","article-title":"Epidemiological Characteristics of Human-Infective RNA Viruses","volume":"5","author":"Woolhouse","year":"2018","journal-title":"Sci Data"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009079","article-title":"Global Discovery of Human-Infective RNA Viruses: A Modelling Analysis","volume":"16","author":"Zhang","year":"2020","journal-title":"PloS Pathog"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1177\/2040206618764483","article-title":"Nucleosides for the Treatment of Respiratory RNA Virus Infections","volume":"26","author":"Jordan","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000797","article-title":"Repurposing of Clinically Approved Drugs for Treatment of Coronavirus Disease 2019 in a 2019-Novel Coronavirus-Related Coronavirus Model","volume":"133","author":"Fan","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa387","article-title":"Transcriptome Analysis of Cepharanthine Against a SARS-CoV-2-Related Coronavirus","volume":"22","author":"Li","year":"2021","journal-title":"Brief Bioinform"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41422-021-00581-y","article-title":"Comparison of Viral RNA-Host Protein Interactomes Across Pathogenic RNA Viruses Informs Rapid Antiviral Drug Discovery for SARS-CoV-2","volume":"32","author":"Zhang","year":"2021","journal-title":"Cell Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1055\/a-1296-7935","article-title":"Favipiravir and COVID-19: A Simplified Summary","volume":"71","author":"Ghasemnejad-Berenji","year":"2021","journal-title":"Drug Res (Stuttg)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12414","article-title":"SARS-CoV-2 Virus Infection: Targets and Antiviral Pharmacological Strategies","volume":"13","author":"Campos","year":"2020","journal-title":"J Evid Based Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102396","article-title":"An Updated Practical Guideline on Use of Molnupiravir and Comparison With Agents Having Emergency Use Authorization for Treatment of COVID-19","volume":"16","author":"Singh","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"B103","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-022-00880-9","article-title":"SARS-CoV-2 Variant Omicron: Currently the Most Complete \u201cEscapee\u201d From Neutralization by Antibodies and Vaccines","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron Escapes the Majority of Existing SARS-CoV-2 Neutralizing Antibodies","author":"Cao","year":"2021","journal-title":"Nature"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable Escape of SARS-CoV-2 Omicron to Antibody Neutralization","volume":"602","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron Extensively But Incompletely Escapes Pfizer BNT162b2 Neutralization","volume":"602","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly Neutralizing Antibodies Overcome SARS-CoV-2 Omicron Antigenic Shift","author":"Cameroni","year":"2021","journal-title":"Nature"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir Remain Active Against SARS-CoV-2 Omicron and Other Variants of Concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antiviral Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron Variant is Highly Sensitive to Molnupiravir, Nirmatrelvir, and the Combination","volume":"71","author":"Li","year":"2022","journal-title":"Cell Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.855496\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T01:41:22Z","timestamp":1649036482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.855496\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":110,"alternative-id":["10.3389\/fimmu.2022.855496"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.855496","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"article-number":"855496"}}